Original Research
This prospective, observational, non-interventional study conducted in six non-Western countries concludes that after 12 months of treatment, clinical and functional outcomes were improved in children and adolescents with attention deficit hyperactivity disorder (ADHD) who initiated and remained on their prescribed pharmacological monotherapy.
Case Report
In this article the author discusses the implications for clinical practice of the results of a recent Phase III trial. He concludes that initial combination of linagliptin plus metformin which was found to be weight neutral, well tolerated and associated with a low frequency of hypoglycaemia, may have advantages for a large proportion of patients with type 2 diabetes, particularly those with a relatively high HbA1c at diagnosis.
Case Report
Over the last decade, an increasing number of clinical trials in cancer research have been incorporating a health-related quality of life (HRQoL) instrument as part of their trial design. In this article the authors discuss the validity and usefulness of a new HRQoL instrument already in use in the United States.
Case Report
In this article the author argues that in type 2 diabetes, an approach that emphasizes diet and exercise and features a treatment regimen tailored to the needs of the individual to reach glycemic targets is warranted in most patients and provides microvascular and cardiovascular benefit, provided that hypoglycemia is avoided.
Case Report
Apixaban, dabigatran and rivaroxaban all have advantages over warfarin for stroke prophylaxis in patients with atrial fibrillation. In this article the author discusses the effect of organ dysfunction on drug disposition, drug–drug interaction potential, and other patient-centered factors to consider when selecting the right antithrombotic therapy for the patient.
